Moneycontrol's Shraddha Sharma gets in conversation with Viswanath Pilla to find out the impact of the USFDA warning on the company.
India's third largest drug-maker Lupin said on Monday that the USFDA has cautioned the company over its Tarapur manufacturing facility, which could come under regulatory action.
In a filing, Lupin said that it had received a communication from the US regulator on an inspection conducted at its manufacturing facility between September 16 and 20 as Official Action Indicated.
In this edition of Reporter’s Take, Moneycontrol's Shraddha Sharma gets in conversation with Viswanath Pilla to find how this development could impact the country.
Watch the video for more.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jan 14, 2020 09:42 pm
